JPRN-UMIN000036253
Recruiting
Phase 3
Randomized controlled phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC) - Randomized controlled phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC)
Japan Clinical Oncology Group (JCOG)0 sites1,050 target enrollmentMarch 19, 2019
ConditionscT3(SS) or cT4a(SE) gastric cancer
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- cT3(SS) or cT4a(SE) gastric cancer
- Sponsor
- Japan Clinical Oncology Group (JCOG)
- Enrollment
- 1050
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Synchronous or metachronous (within 5 years) malignancies. 2\) Infectious disease requiring systemic treatment. 3\) Body temperature of 38 degrees Celsius or higher. 4\) During pregnancy, within 28 days of postparturition, or during lactation. 5\) Severe mental disease. 6\) Receiving continuous systemic corticosteroid or immunosuppressant treatment. 7\)History of unstable angina pectoris within three weeks or myocardial infarction within six months before registration. 8\)Poorly controlled valve disease, dilated or hypertrophic cardiomyopathy 9\)HIV antibody positive 10\)Interstitial pneumonia, pulmonary fibrosis, or severe emphysema based on chest CT
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 Gastric Cancer patients (JCOG1907, MONA LISA study)clinical stage T1-4aN0-3 Gastric CancerJPRN-UMIN000039825Japan Clinical Oncology Group (JCOG)1,040
Completed
Phase 3
Clinical trial, phase 3, to evaluate the efficacy of CVO + for the treatment of COVID-19.COVID-19PACTR202103601407640PHARAMALAGASY338
Active, not recruiting
Not Applicable
Study to evaluate optimized retreatment and prolonged therapy with bortezomibMultiple MyelomaMedDRA version: 17.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-004795-11-NLJanssen-Cilag International N.V.240
Active, not recruiting
Not Applicable
Study to evaluate optimized retreatment and prolonged therapy with bortezomibMultiple MyelomaMedDRA version: 17.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-004795-11-BEJanssen-Cilag International N.V.240
Active, not recruiting
Not Applicable
Study to evaluate optimized retreatment and prolonged therapy with bortezomibMultiple MyelomaMedDRA version: 17.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-004795-11-PLJanssen-Cilag International N.V.240